Zobrazeno 1 - 7
of 7
pro vyhledávání: '"George I. Moonsammy"'
Autor:
Andrée Delem, Leonard N. Binn, Robert F. DeFraites, Charles H. Hoke, David S. Krause, Brian H. Feighner, Philip Macarthy, Devesh D. Kanjarpane, George I. Moonsammy, Margot R. Krauss
Publikováno v:
Journal of Infectious Diseases. 171:S61-S69
To study the feasibility of using inactivated hepatitis A vaccine for rapid immunization of US soldiers, 276 randomized seronegative volunteers received one of four regimens: two injections, on day 0 or one each on day 0 and 14, day 0 and 30, or day
Publikováno v:
Vaccine. 9:807-809
The purpose of this study was to determine if a hepatitis B vaccination schedule initiated with one recombinant DNA vaccine could be completed with another. Forty-eight adults on a hepatitis B vaccination schedule of 0, 1 and 6 months had received th
Autor:
Fadia E. Ali, William E. Bondinell, Penelope A. Dandridge, James S. Frazee, Eleanor Garvey, Gerald R. Girard, Carl Kaiser, Thomas W. Ku, John J. Lafferty, George I. Moonsammy, Hye-Ja Oh, Julia A. Rush, Paulette E. Setler, Orum D. Stringer, Joseph W. Venslavsky, Beth W. Volpe, Libby M. Yunger, Charles L. Zirkle
Publikováno v:
Journal of medicinal chemistry. 28(5)
3-Pyrrolidineacetic acid (1a), certain piperidinecarboxylic acids--i.e., 3-piperidinecarboxylic acid (2a), 1,2,5,6-tetrahydro-3-pyridinecarboxylic acid (3a), and cis-4-hydroxy-3-piperidinecarboxylic acid (4a)--cis-3-aminocyclohexanecarboxylic acid (5
Autor:
Mark A. Stewart, George I. Moonsammy
Publikováno v:
Journal of neurochemistry. 13(12)
Publikováno v:
Clinical Research Practices and Drug Regulatory Affairs. 3:439-439
Publikováno v:
Controlled Clinical Trials. 7:251
of patients were evaluable. Primary reasons for non-evaluability in therapeutic protocols included insufficient evidence of infection (28%), resistant organisms (3), insufficient course of therapy (2$), and underlying disease or complicating factors
Publikováno v:
Clinical Research Practices and Drug Regulatory Affairs. 3:443-443